NCI Drug Dictionary
The search textbox has an autosuggest feature. When you enter three or more characters, a list of up to 10 suggestions will popup under the textbox. Use the arrow keys to move through the suggestions. To select a suggestion, hit the enter key. Using the escape key closes the listbox and puts you back at the textbox. The radio buttons allow you to toggle between having all search items start with or contain the text you entered in the search box.
gallium Ga 68-labeled BNOTA-PRGD2
A radiopharmaceutical agent comprised of a pegylated arginine-glycine-aspartic acid dimer (PRGD2) labeled with gallium Ga 68, with potential alphaVbeta3 integrin imaging activity upon positron emission topography (PET) or single photon emission computed tomography (SPECT). This radiopharmaceutical is prepared by conjugating PRGD2 with chelator S-2-(4-isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid (BNOTA) which is capable of forming a six-coordinate complex with Ga 68. After intravenous administration, gallium Ga 68-labeled BNOTA-PRGD2 binds to alphaVbeta3 integrin on the cell membrane via the cyclic tri-amino acids RGD motif. Upon PET imaging, alphaVbeta3 integrin-expressing tumor cells can be visualized and expression levels can be quantified. Compared to other radiolabeled RGD-containing peptides, this agent shows increased affinity to alphaVbeta3 integrin, enhanced tumor uptake as well as improved pharmacokinetics. alphaVbeta3 integrin is overexpressed on certain tumor cells and tumor endothelial cells while minimally or not expressed on healthy, normal cells and plays a key role in angiogenesis, tumor proliferation and survival. Check for active clinical trials or closed clinical trials using this agent.